Tarlatamab - Amgen
Alternative Names: AMG-757; IMDELLTRA; Imdelltra; IMDYLLTRA; Imdylltra; Tarlatamab-dlleLatest Information Update: 29 Oct 2026
At a glance
- Originator Amgen
- Developer Amgen; BeOne Medicines
- Class Antineoplastics; Bispecific antibodies; Immunoglobulin Fc fragments; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Yes - Small cell lung cancer
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Small cell lung cancer
- Phase I/II Glioma
- Discontinued Malignant melanoma; Prostate cancer
Most Recent Events
- 24 Oct 2026 Efficacy and adverse evenet data from phase III DeLLphi-305 trial in Small cell lung cancer released by Amgen
- 24 Oct 2026 Efficacy and adverse event data from a phase I DeLLphi-303 trial in Small cell lung cancer released by Amgen
- 08 Sep 2026 Efficacy data from phase III DeLLphi-305 trial in Small cell lung cancer released by Amgen